KCM
CLDX icon

Kynam Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Kynam Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-246,400
Closed -$2.48M – 39
2022
Q2 		$2.48M Buy
+246,400
New +$7.16M 0.63% 21

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kynam Capital Management's CLDX Position: Q1 2026 in Review

Kynam Capital Management reduced its Celldex Therapeutics (CLDX) stake by 1.7% in Q1 2026, selling an estimated $2.8M and leaving 5,840,567 shares worth $185M. The position accounts for 11.43% of the portfolio, ranked #2.

Kynam Capital Management first reported a position in CLDX in Q4 2021 and has held it in 18 quarters since. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Kynam Capital Management held 5,840,567 shares of Celldex Therapeutics worth $185M as of Q1 2026.
  • Kynam Capital Management sold 102,613 Celldex Therapeutics shares in Q1 2026, an estimated $2.8M.
  • Celldex Therapeutics made up 11.43% of Kynam Capital Management's portfolio in Q1 2026, its #2 holding.
  • Kynam Capital Management first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.